Helper-independent parvoviruses as gene therapy and vaccine delivery vectors

Parvoviruses

Volumn , Issue , 2005, Pages 571-583

  Cornelis, Jan J ^a   Dinsart, Christiane ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 50349091950     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (85)

1. Arenberg, D. A., Kunkel, S. L., Polverini. et al. 1996. Interferon-±-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human nonsmall cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. Journal of Experimental Medicine 184: 981-92.
2. Avalosse, B., Dupont, F., Spegelaere, P. et al. 1996. Method for concentrating and purifying recombinant autonomous parvovirus vectors designed for tumour-cell-targeted gene therapy. Journal of Virology Methods 62: 179-83.
3. Boisgérault, F., Moron, G. and Leclerc, C. 2002. Virus-like particles: a new family of delivery systems. Expert Review on Vaccines 1: 101-9.
4. Brandenburger, A. and Russell, S. 1996. A novel packaging system for the generation of helper-free oncolytic MVM vector stocks. Gene Therapy 3: 927-31.
5. Brandenburger, A. and Velu, T. 2004. Autonomous parvovirus vectors: preventing the generation of wild-type or replication-competent virus. Journal of Gene Medicine 6 (Suppl.): S203-11.
6. Brandenburger, A., Legendre, D., Avalosse, B. and Rommelaere, J. 1990. NS-1 and NS-2 proteins act synergistically in the cytopathogenicity of parvovirus MVMp. Virology 174; 576-84.
7. Brandenburger, A., Coessens, E., El Bakkouri, K. and Velu, T. 1999. Influence of sequence and size of DNA on packaging efficiency of parvovirus MVM-based vectors. Human Gene Therapy 10: 1229-38.
8. Brown, C., DiSumma, F. M., Rommelaere, J. et al. 2002. Production of recombinant H-1 parvoviruses devoid of replication-competent particles. Human Gene Therapy 13: 2135-45.
9. Brunstein, J. and Astell, C. R. 1997. Analysis of the internal replication sequence indicates that there are three elements required for efficient replication of minute virus of mice minigenomes. Journal of Virology 71: 9087-95.
10. Caillet-Fauquet, P., Perros, M., Brandenburger, A. et al. 1990. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins. EMBO Journal 9: 2989-95.
11. Chapman, M. S. and Rossmann, M. G. 1995. Single-stranded DNAprotein interactions in canine parvovirus. Structure 3: 151-162.
12. Cheong, S. C., Clément, N., Velu, T. and Brandenburger, A. 2003. A novel method for the titration of recombinant virus stocks by ELISPOT assay. Journal of Virology Methods 109: 119-24.
13. Clément, N., Avalosse, B., El Bakkouri, K. et al. 2001. Cloning and sequencing of defective particles derived from the autonomous parvovirus minute virus of mice for the construction of vectors with minimal cis-acting sequences. Journal of Virology 75: 1284-93.
14. Clément, N., Velu, T. and Brandenburger, A. 2002. Construction and production of oncotropic vectors, derived from MVM(p), that share reduced sequence homology with helper plasmids. Cancer Gene Therapy 9: 762-70.
15. Colomar, M. C., Hirt, B. and Beard, P. 1998. Two segments in the genome of the immunosuppressive minute virus of mice determine the host-cell specificity, control viral DNA replication and affect viral RNA metabolism. Journal of General Virology 79: 581-6.
16. Cornelis, J. J., Haag, A., Kornfeld, C. et al. 2000. Autonomous parvovirus vectors. In: A. Cid-Arregui and A. Gancia-Carranca (eds), Viral Vectors: Basic Science and Gene Therapy. Natick, MA: Eaton Publishing, Bio Techniques Books, pp. 97-115.
17. Corsini, J., Carlson, J. O., Maxwell, F. and Maxwell, I. H. 1995. Symmetric-strand packaging of recombinant parvovirus LuIII genomes that retain only the terminal regions. Journal of Virology 69: 2692-6.
18. Corsini, J., Maxwell, I. H., Maxwell, F. and Carlson, J. O. 1996. Expression of parvovirus LuIII NS1 from a Sindbis replicon for production of LuIII-luciferase transducing virus. Virus Research 46: 95-104.
19. Cotmore, S. F. and Tattersall, P. 1994. An asymmetric nucleotide in the parvoviral 3' hairpin directs segregation of a single origin of DNA replication. EMBO Journal 13: 4145-52.
20. Cotmore, S. F. and Tattersall, P. 2005. Genome packaging sense is controlled by the efficiency of the nick site in the right-end replication origin of parvoviruses minute virus of mice and LuIII. Journal of Virology 79: 2287-300.
21. Cotmore, S. F., D'Abramo, A. M. Jr, Carbonell, L-F. et al. 1997. The NS2 polypeptide of parvovirus MVM is required for capsid assembly in murine cells. Virology 231: 267-80.
22. Deleu, L.F., Fuks, D., Spitkovski, R. et al. 1998. Opposite transcriptional effects of cyclic AMP-response elements in confluent or p27KIP-overexpressing cells versus serum-starved or growing cells. Molecular Cell Biology 18: 409-19.
23. Deleu, L., Pujol, A., Faisst, S. and Rommelaere, J. 1999. Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection. Journal of Virology 73: 3877-85.
24. Dinsart, C., Cornelis, J. and Rommelaere, J. 1996. Recombinant autonomous parvoviruses: new tools for the gene therapy of cancer? Chemistry Today 14: 32-8.
25. Dong, J-Y., Fan, P-D. and Frizzell, R. A. 1996. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Human Gene Therapy 7: 2101-12.
26. Dupont, F., Tenenbaum, L., Guo, L. P. et al. 1994. Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein. Journal of Virology 68: 1397-406.
27. Dupont, F., Avalosse, B., Karim, A. et al. 2000. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector. Gene Therapy 7: 790-6.
28. Dupont, F., Karim, A., Dumon, J.-C. et al. 2001. A novel MVMp-based vector system specifically designed to reduce the risk of replication-competent virus generation by homologous recombination. Gene Therapy 8: 921-9.
29. Eichwald, V., Daeffler, L., Klein, M. et al. 2002. The NS2 proteins of parvovirus minute virus of mice are required for efficient nuclear egress of progeny virions in mouse cells. Journal of Virology 76: 10307-19.
30. El Bakkouri, K., Clément, N., Velu, T. and Brandenburger, A. 2000a. Amplification of MVM(p) vectors through serial infection of a new packaging cell line. Tumor Targeting 4: 210-17.
31. El Bakkouri, K., Servais, C., Cheong, S. C. et al. 2005. In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin 2 cDNA. Journal of Gene Medicine 7: 189-97.
32. Gancberg, D., Zeicher, M., Bakkus, M. et al. 2000. Oncoselective transduction of CD80 and CD86 in tumor cell lines using an autonomous recombinant parvovirus. Anti-cancer Research 20: 1825-32.
33. Giese, N., DeMartino, L., Haag, A. et al. 2000. Autonomous parvovirusbased vectors: Potential for gene therapy of cancer. In: G. Gregoriades and B. McCormack (eds), Targeting of Drugs. Ohmsha: IOS Press, pp. 34-52.
34. Giese, N. A., Raykov, Z., DeMartino, L. et al. 2002. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Therapy 9: 432-42.
35. Grimm, D., Kern, A., Pawlita, M. et al. 1999. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Therapy 6: 1322-30.
36. Haag, A., Menten, P., Van Damme, J. et al. 2000. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Human Gene Therapy 11: 597-609.
37. Jacoby, R. O., Ball-Goodrich, L. J., Besselsen, D. G. et al. 1996. Rodent parvovirus infections. Laboratory Animal Science 46: 370-80.
38. Kestler, J., Neeb, B., Struyf, S. et al. 1999. Cis-requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Human Gene Therapy 10: 1619-32.
39. Lang, S. I., Boelz, S., Stroh-Dege, A. Y. et al. 2005. The infectivity and lytic activity of minute virus of mice wild-type and derived vector particles are strikingly different. Journal of Virology 79: 289-98.
40. Linser, P., Bruning, H. and Armentrout, R. W. 1977. Specific binding sites for a parvovirus, minute virus of mice, on cultured mouse cells. Journal of Virology 24: 211-21.
41. Li, X. and Rhode, S, L. 1990. Mutation of lysine 405 to serine in the parvovirus H-1 NS1 abolishes its functions for viral DNA replication, late promoter trans activation, and cytotoxicity. Journal of Virology 64: 4654-60.
42. Malerba, M., Daeffler, L., Rommelaere, J. and Iggo, R. D. 2003. Replicating parvoviruses that target colon cancer cells. Journal of Virology 77: 6683-91.
43. Maxwell, I. H. and Maxwell, F. 1994. A modified plaque assay and infected cell hybridization assay for wild-type and recombinant LuIII autonomous parvovirus. BioTechniques 16: 877-81.
44. Maxwell, I. H. and Maxwell, F. 1999. Control of parvovirus DNA replication by a tetracycline-regulated repressor. Gene Therapy 6: 309-13.
45. Maxwell, I. H., Maxwell, F., Rhode, III. S. L. et al. 1993a. Recombinant LuIII autonomous parvovirus as a transient transducing vector for human cells. Human Gene Therapy 4: 441-50.
46. Maxwell, I. H., Long, C. J., Carlson, J. O. et al. 1993b. Encapsidation of a recombinant LuIII parvovirus genome by H1 virus and the fibrotropic or lymphotropic strains of minute virus of mice. Journal of General Virology 74: 1175-9.
47. Maxwell, I. H., Spitzer, A. L., Maxwell, F. and Pintel, D. J. 1995. The capsid determinant of fibrotropism for the MVMp strain of minute virus of mice functions via VP2 and not VP1. Journal of Virology 69: 5829-32.
48. Maxwell, I. H., Spitzer, A. L., Long, C. J. and Maxwell, F. 1996. Autonomous parvovirus transduction of a gene under control of tissue-specific or inducible promoters. Gene Therapy 3: 28-36.
49. Maxwell, I. H., Chapman, J. T., Scherrer, L. C. et al. 2001. Expansions of tropism of a feline parvovirus to target a human tumor cell line by display of an αv integrin binding peptide on the capsid. Gene Therapy 8: 324-31.
50. Maxwell, I. H., Terrell, K. L. and Maxwell, F. 2002. Autonomous parvovirus vectors. Methods 28: 168-81.
51. Miller, C. L. and Pintel, D. J. 2002. Interaction between parvovirus NS2 protein and nuclear export factor Crm1 is important for viral egress from the nucleus of murine cells. Journal of Virology 76: 3257-66.
52. Moehler, M., Blechacz, B., Weiskopf, N., et al. 2001. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Therapy 8: 158-67.
53. Moehler, M., Zeidler, M., Schede, J. et al. 2003. The oncolytic parvovirus H1 induces release of heat shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. Cancer Gene Therapy 10: 477-80.
54. Momoeda, M., Wong, S., Kawase, M. et al. 1994. A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. Journal of Virology 68: 8443-6.
55. Naeger, L. K., Cater, J. and Pintel, D. J. 1990. The small nonstructural protein (NS2) of the parvovirus minute virus of mice is required for efficient DNA replication and infectious virus production in a cell-type-specific manner. Journal of Virology 64: 6166-75.
56. Olijslagers, S., Dege, A. Y., Dinsart, C. et al. 2001. Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Cancer Gene Therapy 8: 958-65.
57. Palmer, G. A. and Tattersall, P. 2000. Autonomous parvoviruses as gene transfer vehicles. Contrib Microbiol 4: 178-202.
58. Palmer, G. A. and Tattersall, P. 2000. MVM-based vectors for transducing human and murine T cells. 8th Parvovirus Workshop, Mont-Tremblant, Canada, pp. 70-1.
59. Palmer, G. A., Brogdon, J. L., Constant, S. L. and Tattersall, P. 2004. A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation. Journal of Virology 78: 1101-8.
60. Paradiso, P. 1981. Infectious process of the parvovirus H-1: correlation of protein content, particle density, and viral infectivity. Journal of Virology 39: 800-7.
61. Ponnazhagan, S., Weigel, K. A., Raikwar S.P. et al. 1998. Recombinant human parvovirus B19 vectors: Erythroid cell-specific delivery and expression of transduced genes. Journal of Virology 72: 5224-30.
62. Raykov, Z., Legrand, V., Homann, H. and Rommelaere, J. 2002. Transient suppression of transgene expression by means of antisense oligonucleotides: a method for the production of toxin-transducing recombinant viruses. Gene Therapy 9: 358-62.
63. Raykov, Z. M., Balboni, G., Aprahamian, M. and Rommelaere, J. 2004. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. International Journal of Cancer 109: 742-9.
64. Rhode, S. L. III. 1985. Trans-activation of parvovirus P38 promoter by the 76K noncapsid protein. Journal of Virology 55: 886-9.
65. Rhode, S. L. III. 1989. Both excision and replication of cloned autonomous parvovirus DNA require the NS1 (rep) protein. Journal of Virology 63: 4249-56.
66. Rommelaere J, Giese, N., Cziepluch, G. and Cornelis, J. J. 2005. Parvoviruses as anti-cancer agents, In: J. G. Sinkovics and J.C. Horvath (eds), Virus Therapy of Human Cancers. New York: Marcel Dekker, Inc., pp. 627-75.
67. Ronchetti, A., Rovere, P., Iezzi, G. et al. 1999. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. Journal of Immunology 163: 130-6.
68. Russell, S. J., Brandenburger, A., Flemming, C. L. et al. 1992. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. Journal of Virology 66: 2821-8.
69. Sedlik, C., Saron, M.-F., Sarraseca, J. et al. 1997. Recombinant parvoviruslike particles as an antigen carrier: a novel non-replicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proceedings of National Academy of Sciences USA 94: 7503-8.
70. Shabram, P. and Aguilar-Cordova, E-A. 2000. Multiplicity of infection/ multiplicity of confusion. Molecular Therapy 2: 420-1.
71. Somersan, S., Larsson, M., Fonteneau, J. F. et al. 2001. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. Journal of Immunology 167: 4844-52.
72. Spitzer, A. L., Maxwell, F., Corsini, J. and Maxwell, I. H. 1996. Species specificity for transduction of cultured cells by a recombinant LuIII rodent parvovirus genome encapsidated by canine parvovirus or feline panleukopenia virus. Journal of General Virology 77: 1787-92.
73. Spitzer, A. L., Parrish, C. R. and Maxwell, I. H. 1997. Tropic determinant for canine parvovirus and feline panleukopenia virus functions through the capsid protein VP2. Journal of General Virology 78: 925-8.
74. Srivastava, C. H, Samulski, R. J., Lu, L. et al. 1989. Construction of a recombinant human parvovirus B19: adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus. Proceedings of National Academy Science USA 86: 8078-82.
75. Tam, P. and Astell, C. R. 1993. Replication of minute virus of mice minichromosomes: novel replication elements required for MVM DNA replication. Virology 193: 812-24.
76. Tattersall, P. 1972. Replication of the parvovirus MVM. I. Dependence of virus multiplication and plaque formation on cell growth. Journal of Virology 10: 586-90.
77. Tattersall, P. and Bratton, J. 1983. Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice. Journal of Virology 46: 944-55.
78. Tijssen, P., Bergeron, J., Dubuc, R. and Hébert, B. 1995. Minor genetic changes among porcine parvovirus groups are responsible for major distinguishing biological properties. Seminars in Virology 6: 319-28.
79. Truyen, U. and Parrish, C. R. 1995. The evolution and control of parvovirus host ranges. Seminars in Virology 6: 311-17.
80. Wang, X-S, Yoder, M. C., Thou, S. Z. and Srivastava, A. 1995. Parvovirus B19 promoter at map unit 6 confers autonomous replication competence and erytroid specificity to adenoassociated virus 2 in primary human hematopoietic progenitor cells. Proceedings of National Academy Science USA 92: 12416-20.
81. Weigel-Kelley, K. A., Yoder, M. C. and Srivastava, A. 2001. Recombinant human parvovirus B19 vectors: Erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. Journal of Virology 75: 4110-16.
82. Wetzel, K. 2000. Untersuchung MCP-3-rekombinanter Parvoviren zur Gentherapie von Krebs: Vorklinische Studien in zwei Tiermodellen. PhD. thesis, University of Heidelberg, Germany.
83. Wetzel, K., Menten, P., Opdenakker, G. et al. 2001. Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts. Journal of Gene Medicine 3: 326-37.
84. Wrzesinski, C., Tesfay, L., Salome, N. et al. 2003. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. Journal of Virology 77: 3851-8.
85. Zolotukhin, S., Byrne, B. J., Mason, E. et al. 1999. Recombinant adenoassociated virus purification using novel methods improves infectious titer and yield. Gene Therapy 6: 973-85.